Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

March 10, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

March 28, 2020

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

March 11, 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

March 10, 2018

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

March 14, 2015

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.